Synergy San Diego

Lemon Grove, California 92064

2 studies enrolling now · 39 studies all time

What they study most

Acute Migraine, Adjunctive Treatment of Major Depressive Disorder, Alcohol Use Disorder, Antipsychotic Agents, Bipolar Disorder, Bipolar I Disorder, Cannabis Withdrawal, Central Nervous System Depressants, Cognitive Impairment Associated With Schizophrenia, Depressive Disorder, Major, Diabetes Mellitus, Type 2, Episodic Migraine

Studies at this site

• Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE. — Recruiting now
• Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia — Recruiting now
• A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder — Completed
• A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder — Running, not enrolling
• Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients — Completed
• BHV-7000 Acute Treatment of Bipolar Mania — Completed
• BHV-7000 Open-Label Extension Bipolar Mania Study — Stopped early
• A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication — Completed
• A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine — Completed
• ERG Components in Schizophrenia and Bipolar Disorder Type I — Running, not enrolling
• Randomized, Placebo-controlled Trial of Ferric Carboxymaltose in RLS Patients With Iron-deficiency Anemia — Stopped early
• A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention — Stopped early
• An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4) — Completed
• Effect of PP-01 on Cannabis Withdrawal Syndrome — Completed
• A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms — Stopped early
• Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults — Completed
• A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD — Completed
• Randomized Trial of Adult Participants With Generalized Anxiety Disorder — Completed
• A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia — Completed
• A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2) — Completed
• This Study Tests Whether BI 425809 Together With Brain Training Using a Computer Improves Mental Functioning in Patients With Schizophrenia — Completed
• A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder — Completed
• Acute Treatment Trial in Adult Subjects With Migraines — Completed
• Assessment of Methadone and Buprenorphine in Interstitial Fluid — Completed
• Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine — Completed
• Relative Bioavailability of LY03010 Compared to Listed Drug — Completed
• Randomized Trial in Adult Participants With Acute Migraines — Completed
• A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) — Completed
• Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With Schizophrenia — Stopped early
• Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment — Stopped early
• Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment — Completed
• Prediabetes and Type 2 Diabetes Data Collection Study — Status unconfirmed
• A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite® — Stopped early
• A Multiple Ascending Dose Trial of CVL-231 in Subjects With Schizophrenia — Completed
• Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine — Completed
• Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia — Completed
• Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder — Completed
• A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder — Completed
• A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01) — Completed